March 9, 2021
Authored and Edited by Shannon M. Patrick; Kara A. Specht; Elizabeth D. Ferrill
In Bayer Healthcare LLC v. Baxalta Inc., No. 19-2418 (Fed. Cir. Mar. 1, 2021), the Federal Circuit reviewed many issues on appeal, including Baxalta’s Seventh Amendment challenge.
Baxalta argued that the district court violated the company’s Seventh Amendment right to a jury trial by awarding Bayer pre-verdict supplemental damages. The jury calculated damages between June 14, 2016 and November 30, 2018. The district court then awarded Bayer pre-verdict supplemental damages for the period between December 1, 2018 and the date the judgment was entered, February 8, 2019.
The Federal Circuit upheld the pre-verdict supplemental damages award. Although the Court noted that an additur would violate the Seventh Amendment, it found that the district court’s award was a proper damages award under 35 U.S.C. § 284, which gives the district court the ability to assess damages for the claimant that were not found by the jury. In awarding damages, the district court merely applied “the jury’s royalty rate to the undisputed actual infringing sales base” to calculate the damages. Slip op. at 32. Therefore, the district court’s pre-verdict damages award did not constitute “an impermissible additur or an otherwise ‘bald addition of something which in no sense can be said to be included in the verdict.’” Id. at 33.
Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
May 20, 2026
Webinar
Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement
May 18, 2026
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.